Company ProfilePremium

Benoholdings, Inc.

Company Profile Analysis

Ticker: 206400.KQ주식회사 아인스팩씨엔에스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Benoholdings, Inc. - Company showcase

Year Founded & Workforce

2001

22 Employees

Benoholdings, Inc. logo

Benoholdings, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Benoholdings, Inc. Overview

AinsFac CNS is a loss-making KOSDAQ micro-cap holding company with a history of repeated reinvention. It began in 2001 as Entermate, an internet-service and online/mobile game publisher focused on Chinese-language titles. In 2020 it became Benoholdings and pivoted toward biotech by taking control of Beno Bio. In 2023 it became BENO TNR, adding:

  • an interior-construction business (exterior shading systems, eco double-floor systems, radiant heating and cooling panels);

  • a controlling stake in Canadian wearable-exoskeleton developer Human in Motion Robotics (product: XoMotion).

In 2026 it bought a duct-manufacturing business. It then changed control to a new technology investment fund and was renamed AinsFac CNS. Its articles now list semiconductor, display, solar and battery equipment, smart-factory automation, recycling and energy-storage businesses, none of which yet generates disclosed revenue.

Operating revenue is small: about KRW 3.6bn over the trailing twelve months to June 2026. The equity value sits largely in investments and intangibles. The investment case is therefore driven less by current operations than by:

  • the new owner's capital injection;

  • the company's ability to stay listed under Korea's tightened 2026 delisting rules;

  • whether the robotics and bio affiliates ever produce revenue.


What the company does today

The H1 2026 interim report, as summarised by Bloter (15 Sep 2026), describes the company's main business as interior construction and duct manufacturing:

  • H1 2026 revenue was about KRW 1.4bn.

  • Duct manufacturing contributed about KRW 0.7bn, roughly half of the total.

  • The duct business was acquired in 2026 from 금영이엔씨 (Geumyoung E&C) for about KRW 0.8bn.

Butler.works, which aggregates DART data, gives a Q2 2026 revenue mix of Construction 54% / Duct manufacturing 46%.

Korean Wikipedia and Bullstory describe the operating scope as follows:

Interior construction: development, design, manufacture and installation of building shading systems (차양시스템), eco-friendly double/raised flooring (친환경 이중바닥재) and radiant heating/cooling systems (복사냉난방시스템).

Wearable robotics: through Human in Motion Robotics Inc. (Canada) and Human in Motion Robotics Asia (Korea JV). The flagship is the lower-limb, self-balancing exoskeleton XoMotion; XoMotion-R is the rehabilitation model.

Bio: through Beno Bio (베노바이오), an affiliate doing drug discovery. Its disclosed work includes an epigenetics-based drug programme, an injectable composition for a next-generation macular-degeneration therapy (patent registered mid-2026) and a Pan-KRAS programme.

Duct manufacturing: acquired 2026.

New objects added to the articles at the 29 Sep 2026 EGM: - Equipment for semiconductors, LCD, OLED, solar and secondary batteries.

  • Ultrapure-water and water-purification plant.

  • Smart-factory logistics automation.

  • Recycling of waste batteries and waste solar panels.

  • Energy storage systems (ESS) and EV charging. No investment amounts or commercialisation timelines have been disclosed for these (Bloter; Money Today via Nate).

Business and revenue model

Revenue model elementStatusComment
Project/contract revenue (interior construction)ActiveProject-based, lumpy. A "single sales/supply contract" was disclosed on 30 Jul 2026 (Butler.works filing list); its value is not disclosed in reviewed sources.
Product manufacturing revenue (ducts)Active from 2026About KRW 0.7bn in H1 2026 (Bloter)
Product sales (exoskeletons)Pre-commercial in KoreaHuman in Motion Robotics Asia had no revenue in H1 2026 and a net loss of about KRW 0.5bn (Bloter). XoMotion-R received Health Canada approval and a first sales contract was reported in Jan 2025 (Asia Economy).
Licensing / technology export (bio)No disclosed revenueBeno Bio's stated route is clinical development, technology export and co-research (Asia Economy, Nov 2020).
Game publishing (legacy Entermate)Status not publicly disclosedIn 2020 the CEO said the game publishing business was expected to remain operating-profitable. No current game revenue is visible in 2026 segment data.
Subscription——

Value-chain position, customers and end markets

BusinessValue-chain positionCustomer typesEnd market
Interior constructionDesign-manufacture-install specialist subcontractorBuilding owners, general contractors (named customers not publicly disclosed)Korean commercial and residential building fit-out
Duct manufacturingComponent manufacturerConstruction and HVAC contractors (not publicly disclosed)Building HVAC
Wearable roboticsDevice OEM (design, development, regulatory approval) with distribution partnersRehabilitation hospitals and clinics; distributors such as Robotimize (Singapore)Rehabilitation and assistive medical devices
BioEarly-stage drug discoveryProspective licensees and pharma partnersOphthalmology (macular degeneration), oncology (KRAS)

Company self-description vs. independent characterisation

Company's own description: (per its trade-name and EGM filings): the purpose of the 2026 rename and objects expansion is "achieving management objectives and business diversification" (paraphrased from the DART change-of-trade-name filing reported by Digital Today).

Independent characterisation: a capital-markets vehicle whose operating businesses are sub-scale. Three points support this:

  • Revenue trend. Revenue fell from KRW 25.3bn (FY2024) to KRW 4.77bn (FY2025) and is about KRW 3.6bn TTM (Butler.works; Valueline).

  • Losses. Operating losses have occurred every year since FY2022.

  • Financing-heavy history. Strategy has repeatedly been carried by control transactions, renames and financing rather than organic growth. Recent examples:

    • 2023: control change and rename to BENO TNR.

    • 2025: a KRW 30bn financing plan with Haemil IB.

    • 2026: control sale at a roughly 600% premium, a rename, a 10x increase in authorised share capital and a 50x increase in convertible-bond capacity.

Strategy

Stated strategy themes

Benoholdings era (2020):

  • Keep game publishing operating-profitable.

  • Launch new games in 2021.

  • Expand through new-drug R&D centred on Beno Bio.

Source: CEO Jeong Jip-hun, Asia Economy (Nov 2020).

BENO TNR era (2023–2026):

  • Become a global wearable-robot company. Management cited growth above 42% per year for the global wearable-robot market (a company-cited figure).

  • Add AI software capability through the 2024 Alticast investment.

  • Expand toward AI humanoid robotics.

  • Take Human in Motion Robotics public on KOSDAQ via a technology-special listing (IPO mandate Oct 2025).

Sources: eToday; Asia Economy.

AinsFac CNS era (Sep 2026–):

  • Business diversification into semiconductor, display, solar and battery equipment, ultrapure water, smart-factory automation, battery and solar recycling, ESS and EV charging.

  • Substantial increase in financing capacity.

  • No targets, capex plans or timelines disclosed.

Source: Bloter; Money Today via Nate.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Alticast investmentDec 2024Rights issue plus perpetual CB investment, aimed at robot software and AI synergiesCompleted Dec 2024. Outcome and value not publicly disclosed.
XoMotion-R commercialisationJan 2025Health Canada approval; first sales contractRevenue contribution not publicly disclosed
ASEAN distribution (Robotimize)Mar 2025Sales and strategic partnershipNo revenue disclosed; HMR Asia had zero revenue in H1 2026
Haemil IB KRW 30bn financingJul 2025KRW 10bn CB plus KRW 20bn rights issue—
HMR KOSDAQ IPO preparationOct 2025Eugene Investment & Securities appointed as lead managerPending
K-Humanoid Alliance participation (HMR Asia)2,025Selected as a participating companyOngoing
Duct manufacturing acquisition2,026Geumyoung E&C duct business, about KRW 0.8bnCompleted; about 46% of Q2 2026 revenue
Control change and recapitalisationJul–Dec 2026KRW 33.96bn share purchase plus KRW 10bn placementShare purchase closed 28 Sep; placement due 23 Dec 2026
Delisting-risk remediationSep–Oct 20262:1 consolidation (scheduled 16 Oct) and 5:1 capital reduction (scheduled 29 Oct). The stated purpose of the reduction was changed in a 14 Sep correction from deficit offset to capital efficiency and share-price stabilisation.Scheduled
Articles amendment29 Sep 2026Authorised shares 500m → 5bn. CB and BW limits KRW 300bn → KRW 5tn each. EB limit KRW 100bn → KRW 5tn.EGM agenda per Bloter

Medium-term targets and guidance

None publicly disclosed. The 2015 target of KRW 100bn+ revenue by 2020 was not achieved: peak disclosed revenue in FY2021–FY2025 was KRW 26.7bn.

ESG / sustainability commitments

None publicly disclosed.

Products & Services

Interior construction

Product / serviceDescriptionTarget customerLaunch yearPricingSource
Shading systems (차양시스템)Development, design, manufacture and installation of building shading systemsCommercial and residential building projects—Project-based; not publicly disclosedKorean Wikipedia; Bullstory
Eco-friendly double/raised floor (친환경 이중바닥재)Raised-floor systems: design and installationOffice and commercial fit-out—Project-basedKorean Wikipedia
Radiant heating/cooling systems (복사냉난방시스템)Radiant panel heating and cooling: development, design, installationBuilding owners and contractors—Project-basedKorean Wikipedia; Bullstory

Duct manufacturing

ProductDescriptionSource
DuctsManufactured ducts (business acquired from Geumyoung E&C in 2026 for about KRW 0.8bn). About KRW 0.7bn of H1 2026 revenue. Product specifications not publicly disclosed.Bloter

Wearable robotics (Human in Motion Robotics / HMR Asia)

ProductDescription and capabilitiesTarget customerStatus / versionSource
XoMotionLower-limb bipedal exoskeleton with self-balancing that lets users with paraplegia walk without crutches ("hands-free"). Has 12 actuators and intelligent software for natural gait, and was demonstrated climbing stairs. The company claims a torque-to-weight ratio 2.9x that of Tesla's Optimus (company claim).People with lower-limb paralysis; rehabilitation centresUnveiled in Korea 26 Oct 2023Asia Economy (Dec 2023); eToday (Oct 2023)
XoMotion-RRehabilitation-therapy versionRehabilitation hospitals and clinicsHealth Canada approval and first sales contract (reported Jan 2025). US FDA and Korean MFDS approvals were in progress as of Oct 2025.Asia Economy (Jan 2025; Oct 2025)
Personal-use modelModel for daily use by people with gait impairment, with enhanced AIIndividual usersUnder development (Oct 2025)Asia Economy (Oct 2025)
AI humanoid robotics (aspirational)Stated ambition to extend from wearables to AI-based humanoid robots. Discussions on AI and robotics R&D with Nvidia were described by the company.—Concept stage; no product disclosedAsia Economy (Oct 2025)

Bio (Beno Bio)

ProgrammeDescriptionStageSource
Next-generation macular-degeneration injection compositionInjectable formulation; patent registeredPatent registered (reported June 2026); clinical stage not publicly disclosedStockHub headline citing Asia Economy (Jun 2026)
Pan-KRAS programmeOncology candidate selected for the "2026 Global Company Collaboration Program"Preclinical/early (not publicly disclosed)Asia Economy related-article listing (2026)
Epigenetics-based drug candidatesDrug research using epigeneticsResearch stageBullstory company profile

Legacy game publishing (Entermate)

TitleFormatYearCurrent status
Shinsundo (신선도)Web game (Chinese localisation)2,012—
Waryong Jeonseol (와룡전설), Amheuk Samguk (암흑삼국), Cheonnyeondo (천년도)Web games2012–2015—
I Love Three Kingdoms for Kakao; Be My Slave for Kakao; 1-Minute RPG for KakaoMobile (Kakao)2013–—
Arcane (아케인)Mobile RPGOct 2015—

Source for this table: iNews24 (Oct 2015). In 2015 the company said it operated about 20 games in Korea, eight of which earned more than KRW 1bn each in 2014.

New business objects (added to the articles, Sept 2026, no products yet)

ObjectStatus
Semiconductor, LCD, OLED, solar and secondary-battery equipmentArticles only; no products, investment or timeline disclosed
Ultrapure-water and water-purification plant; water treatmentArticles only
Smart-factory logistics automationArticles only
Waste-battery and waste-solar-panel recyclingArticles only
ESS; EV chargingArticles only

Sources for this table: Bloter; Money Today via Nate (15 Sep 2026).

Financial Narrative

Basis. Consolidated, K-IFRS. Annual figures FY2021–FY2024 are from Butler.works (DART-derived, rounded to KRW 0.1bn). FY2025 figures are from the annual-report values in Korean Wikipedia's infobox (KRW 4,774,718,589 / −5,361,474,305 / −24,026,574,843), which agree with Butler.works. Readers should reconcile against the DART business reports before relying on them.

Interim and trailing data: notes and sources

Source: Dealsite (20 Aug 2026), citing the H1 2026 report. Revenue fell 44% YoY and the operating loss widened 74%.

Source: Valueline trailing-twelve-month series (displayed in 억원). This is consistent with FY2025 KRW 4.77bn − H1 2025 KRW 2.57bn + H1 2026 KRW 1.44bn = KRW 3.64bn.

Balance sheet

Equity-decline note. Equity fell KRW 6.3bn in six months. That is roughly 2.2x the H1 operating loss, which implies further non-operating losses, valuation changes or other comprehensive-income charges in H1 2026. The breakdown is not publicly disclosed in reviewed sources.

Cash flow

Known external financing events:

  • Dec 2024: investment into Alticast (cash outflow; amount not publicly disclosed).

  • Dec 2026 (scheduled): KRW 10bn placement to Acro Fund No.241 for working capital.

Commentary on trends, inflections and drivers

Structural revenue collapse with one anomalous year: Revenue shrank from KRW 26.7bn (FY2021) to KRW 9.9bn (FY2023), spiked to KRW 25.3bn in FY2024, then fell 81% to KRW 4.77bn in FY2025. Reviewed sources do not explain the FY2024 spike and FY2025 collapse. The pattern is consistent with either one or more large, non-recurring construction projects or a change in what was consolidated; the cause should be checked in the FY2024 and FY2025 business reports. The trailing series (KRW 11.2bn → 3.6bn over four quarters) shows the decline is still under way.

Persistent operating losses: The company has lost money at the operating level for four straight years, with KRW 24.0bn of cumulative operating losses over FY2022–FY2025. The FY2025 loss of KRW 5.36bn narrowed by about 45% in absolute terms but was larger than revenue (operating margin −112%). H1 2026 deteriorated again, with the loss widening 74% YoY on 44% lower revenue. Dealsite attributes this to falling sales combined with SG&A burden.

Below-the-line losses dominate: In FY2022 the net loss (KRW −21.9bn) was more than ten times the operating loss. In FY2025 the KRW −24.0bn net loss exceeded the KRW −5.4bn operating loss by about KRW 18.7bn. This is consistent with valuation or impairment losses on the investment portfolio (Beno Bio, Human in Motion Robotics, Alticast), but the components are not publicly disclosed in reviewed sources and are not presented here as fact.

FY2021 profit was non-operating: The FY2021 net profit (KRW 8.6bn) was well above operating profit (KRW 1.5bn), again pointing to non-operating gains whose nature is not publicly disclosed.

  • Equity cushion is eroding but still substantial relative to market value. Equity of KRW 65.6bn against a market cap of about KRW 23bn means the market applies a deep discount (P/B about 0.35x) to the carrying value of the investment-heavy balance sheet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipStakeActivitySource

AinsFac CNS Co., Ltd.

Listed parent

—

Interior construction, duct manufacturing, holding of investments

DART / Bloter

Human in Motion Robotics Inc. (Canada)

Affiliate/subsidiary

45.1% at entry (May 2023); described as largest shareholder. Current stake not publicly disclosed.

Wearable exoskeleton developer (XoMotion)

News Tomato (2023)

Human in Motion Robotics Asia (Korea)

Subsidiary (JV)

60%

Development, APAC sales, intended global production base

eToday (2023); Bloter (2026)

Beno Bio (베노바이오)

Affiliate

33% at Nov 2020. Current stake not publicly disclosed.

Drug discovery

Asia Economy (2020)

Alticast Corp. (KOSDAQ 085810)

Investee

Rights issue plus perpetual CB investment (Dec 2024). Current stake and accounting treatment not publicly disclosed.

Software (Alticast's own 2026 portfolio includes 대현기건 and 압타머사이언스)

Asia Economy (Dec 2024; Apr 2026)

Duct manufacturing business (ex-Geumyoung E&C)

Acquired business (asset deal)

100% of business

Duct manufacturing

Bloter (2026)

Segment Revenue

SegmentContentsH1 2026 revenue (KRW Bn)Share of revenue (Q2 2026 basis)Source

Construction (interior)

Shading systems, double-floor systems, radiant heating and cooling

About 0.7 (by difference)

54%

Bloter; Butler.works

Duct manufacturing

Ducts (acquired 2026)

About 0.7

46%

Bloter; Butler.works

Robotics

Human in Motion Robotics Asia (consolidated, 60%)

0.00%

Bloter

Bio

Beno Bio (equity-accounted or investment; treatment not publicly disclosed)

———

Total (consolidated)

—

1.44

100%

Dealsite (H1 revenue KRW 1,435.17m)

Segment metric

Status

———

Segment redefinitions or restatements

Duct manufacturing is a new segment in 2026. Earlier restatements are not publicly disclosed.

———

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

26.721.89.925.34.77

Operating income (KRW Bn)

1.5-1.9-7.0-9.7-5.36

Net income (KRW Bn)

8.6-21.9-7.9-3.6-24.03

Revenue growth YoY (%)

—-18.4-54.6155.6-81.1

Operating margin (%)

5.6-8.7-70.7-38.3-112.3

Net margin (%)

32.2-100.5-79.8-14.2-503.2

Metric

Value

Basis

———

Revenue CAGR FY2021–FY2025

about −34.9% per year

Computed from the table above

———

Gross profit

—

Not found in reviewed sources

———

EBITDA

—

Not found in reviewed sources

———

Pre-tax income

—

Not found in reviewed sources

———

EPS (basic/diluted) by year

—

TTM EPS of −₩311 per Investing.com (Aug–Sep 2026)

———

Dividends per share

0 in all years

StockHub dividend yield 0.00%; no dividend found

———

“—” = not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricH1 2025H1 2026

Revenue (KRW Bn)

2.571.44

Operating income (KRW Bn)

-1.62-2.82

Income Statement (Quarterly)

MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

TTM revenue (KRW Bn)

11.226.744.774.303.64

Balance Sheet

Item31 Dec 202530 Jun 2026Source

Total equity (KRW Bn)

71.965.6

Bloter (H1 2026 report)

Share capital (KRW Bn)

About 18.8

About 18.8 (falls to about 3.8 after capital reduction)

Money Today via Nate; Bloter

Financial Analysis

ItemFY2021–FY2025

Dividends paid

0 (no dividends found)

Buybacks

None found; treasury share ratio 0.00% (Butler.works)

Financial Analysis — ROE

RatioValueBasis / source

ROE (TTM)

−22.4%

Valueline (Sep 2026)

ROE (TTM, alternative)

−24.43%

StockHub (Jul 2026)

ROE (FY2025, on year-end equity)

about −33.4%

Computed: −24.03 / 71.9

P/B

0.37x

Valueline (22 Sep 2026, ₩678)

P/B (computed)

about 0.35x

KRW 23.2bn market cap / KRW 65.6bn equity, 12 Oct 2026

P/E

Not meaningful (losses); Valueline shows −1.67x

Valueline

Price/Sales (TTM)

about 6.4x

Computed: KRW 23.2bn / KRW 3.64bn TTM revenue

Geographic Revenue

ItemDisclosure

Geographic split (Korea vs. overseas), 3 years

Not publicly disclosed in a comparable series. Valueline's breakdown shows a domestic line (in 억원) and an export line marked N/A, which suggests revenue is overwhelmingly domestic.

Overseas activity

Canada: Human in Motion Robotics (development; first XoMotion-R sales, 2025). ASEAN: distribution partnership with Robotimize (Singapore; targeting Singapore, Malaysia, Indonesia). Historical (2014–2015): Taiwan subsidiary and a Hong Kong JV for games.

Fastest-growing region

Cannot be determined. Overseas robotics sales exist but are not quantified.

Declining region

Domestic (Korea) construction revenue is the main source of the FY2025–H1 2026 decline.

Share Price History

DateClose / priceNoteSource

29 May 2025

1,820

Market cap KRW 70.7bn; 1-year −44.6%

Simply Wall St

6 Jul 2026

1,138

Limit-up intraday (₩1,323) on control-change news

Edaily; Dealsite

8 Jul 2026

996

First close below ₩1,000

Dealsite

23 Jul 2026

760—

Dealsite; Bullstory

18 Aug 2026

990—

Dealsite

About 20 Aug 2026

1,003

One session above ₩1,000

Dealsite

28 Aug 2026

943—

Dealsite

17 Sep 2026

664—

MyDailyByte

22 Sep 2026

678

Market cap about KRW 24.6bn

Valueline

29 Sep 2026

949

+23.41% on EGM day

Digital Today

12 Oct 2026

619

−7.61%; market cap about KRW 23.2bn

StockHub

Share Price & Returns

PeriodReturnSource

1-year

About −63.5% to −66.6% (as of Aug–Sep 2026)

Investing.com

52-week range

₩550–₩2,550 (as of 12 Oct 2026); earlier displays show ₩674–₩2,775

StockHub; Investing.com

3-year / 5-year

Not publicly disclosed in reviewed sources

—

Stock splits

Investing.com reports three past splits (details not publicly disclosed). A further 2:1 consolidation is scheduled for 16 Oct 2026.

Investing.com; Money Today

Valuation Multiples

MultipleAinsFac CNS

P/E

n/m (losses)

EV/EBITDA

n/m (negative EBITDA likely; EBITDA not disclosed)

EV/Sales

Not computable (net debt not disclosed). Price/Sales about 6.4x TTM.

P/B

0.35–0.37x

Capital Markets

ItemStatusSource

Analyst consensus

None (0 reports)

StockHub

Dividend history and policy

No dividends; yield 0.00%

StockHub

Buyback authorisations

None; treasury shares 0.00%

Butler.works

Credit ratings (Moody's / S&P / Fitch)

None (unrated)

—

Action Details

ActionDateEffect

2:1 share consolidation

16 Oct 2026 (scheduled)

Par value ₩500 → ₩1,000

5:1 capital reduction (no consideration)

29 Oct 2026 (scheduled)

Shares 37.51m → about 3.75m (combined with the consolidation). Share capital about KRW 18.8bn → about KRW 3.8bn. Theoretical price ×10.

Third-party placement

23 Dec 2026

KRW 10bn; Acro stake to about 33.5%

Authorised capital and debt-linked limits

Per EGM agenda

Authorised shares 5bn; CB and BW limits KRW 5tn each; EB limit KRW 5tn

Analyst Conclusions

Management guidance and consensus

Management guidance: none publicly disclosed.

Consensus estimates: none (no coverage).

Bull case (grounded in disclosed data)

  1. Recapitalised by a committed owner. The new controller paid KRW 33.96bn in cash for 12.75% and is contracted to inject KRW 10bn more by 23 Dec 2026. That roughly KRW 44bn of commitment is almost twice the current market cap and signals a far higher private valuation.

  2. Asset backing. Book equity of KRW 65.6bn against about KRW 23bn of market value (P/B about 0.35x) leaves room for a re-rating if the investment portfolio is real and realisable.

  3. Robotics optionality. HMR has differentiated technology (CES 2025 award, Health Canada approval), an IPO mandate and an ASEAN distributor. A successful HMR listing could surface value for the parent's stake.

Bear case (grounded in disclosed data)

  1. Operations are shrinking toward irrelevance. TTM revenue is KRW 3.6bn, operating losses persist and H1 2026 losses rose 74%.

  2. Listing risk is acute. The price was below ₩1,000 for most of Jul–Oct 2026 and market cap is near the KRW 20bn floor, which rises to KRW 30bn in January 2027. Korean evidence shows 83% of 2026 consolidations were followed by price declines.

  3. Governance and dilution. The controller premium versus discounted placement, unusual trading concentration, two payment delays and a 50x increase in convertible capacity together raise a high risk that minority value is transferred elsewhere.

Key catalysts and monitorables (next 12 months)

  1. Completion of the 16 Oct consolidation and 29 Oct capital reduction, and the post-relisting price relative to the ₩1,000 and market-cap thresholds.

  2. Payment of the KRW 10bn placement on 23 Dec 2026.

  3. Any formal administrative-issue designation and the subsequent 90-day / 45-day compliance window.

  4. Disclosure of the new co-CEOs' business plan and any first investments in the new sectors.

  5. Any CB, BW or EB issuance under the expanded limits.

  6. The FY2026 business report (March 2027): revenue, impairments, auditor's opinion and any going-concern emphasis.

  7. Progress on the HMR IPO filing and on FDA/MFDS approvals for XoMotion-R.

  8. Beno Bio licensing or clinical milestones.

Analyst verdict

AinsFac CNS is best understood as a listed shell-in-transition, not an operating growth company.

How the business got here. Over a decade the entity has moved through several identities:

  • a Chinese-game publisher;

  • a bio holding company;

  • an interior-construction and exoskeleton group;

  • now a self-declared platform for semiconductor, battery, energy and recycling businesses.

Each identity arrived with a change of control or a rename rather than with organic operating success.

What the numbers show. Revenue has fallen from KRW 26.7bn in FY2021 to about KRW 3.6bn on a trailing basis. Operating losses have run for four years. Net losses repeatedly exceed operating losses, which suggests a balance sheet whose carrying values are at risk.

The bull and bear arguments. The strongest bull argument is arithmetic. Book equity of KRW 65.6bn and roughly KRW 44bn of fresh controller commitments sit against a market value near KRW 23bn. The new owner, whose fund is majority-backed by the similarly named 아인스팩, presumably intends to use the listing and its newly enlarged financing capacity to acquire or build businesses. However, the same features that create upside create risk:

  • authorised shares up tenfold, and convertible capacity raised to KRW 5tn;

  • a history of trading irregularities and minority-unfriendly pricing;

  • a regulatory regime that is now actively delisting penny stocks and sub-scale issuers.

Assessment. Shareholder outcomes over the next 12 months will depend almost entirely on capital-markets events: whether the share consolidation holds, whether the December placement is paid, and what the new management does with the expanded financing authority. Underlying fundamentals will matter far less. Until the company publishes a credible business plan with committed capital, and survives the 2027 market-cap test, the equity should be treated as a high-risk special situation. Its outcome distribution includes delisting, heavy dilution or a reverse-merger-style reinvention. The robotics and bio assets provide some real but unquantified option value, which current disclosure does not allow investors to price.

Overall rating (qualitative): Speculative / high risk. Insufficient disclosure for a fundamental valuation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackgroundSource

Shin Dong-beom (신동범)

Co-CEO; inside director

From Sep 2026

Not publicly disclosed in reviewed sources

Korean Wikipedia; Bloter (nominee)

Kim Jeong-min (김정민)

Co-CEO; inside director

From Sep 2026

Not publicly disclosed in reviewed sources

Korean Wikipedia; Bloter (nominee)

Lee Gyo-in (이교인)

Independent director (nominee at the 29 Sep 2026 EGM)

From Sep 2026 (if elected)

—

Bloter

“—” = not publicly disclosed.

Executive Leadership Team

NameRolePeriodNotesSource

Lee Tae-hyun (이태현)

CEO, Entermate

Around 2015

Led the 2015 SPAC listing. Some data providers (Simply Wall St) still list him as CEO, which is out of date.

iNews24; Simply Wall St

Jeong Jip-hun (정집훈)

CEO, Benoholdings / BENO TNR

About 2020 to Sep 2026

Certified public accountant. Held 26.73% of Lamicus (2023). Sold 230,000 personal shares (0.61%) to Acro in Sep 2026.

Sidae Ilbo; Asia Economy; DART via Special Times

Park Hyung-jun (박형준)

Chairman; controlled the company via Lamicus (73.27% of Lamicus)

2023–2026

Described as an M&A specialist. Spouse Ko Seong-hee was the largest holder of the prior controlling shareholder, J&J Investment. Exited in 2026 at roughly double his investment over about five years.

Sidae Ilbo; Chosun Biz via Daum

Kim Sung-wook (김성욱)

CEO, Beno Bio

2020 (current status not publicly disclosed)

—

Asia Economy (2020)

Siamak Arzanpour

Co-founder and CEO, Human in Motion Robotics

Current as of 2023

Simon Fraser University engineering professor

News Tomato; Asia Economy

Park Jung-wook (Edward Park)

Co-founder, Human in Motion Robotics; co-CEO, HMR Asia

Current as of 2025

Simon Fraser University professor; keynote speaker at the Korean Academy of Rehabilitation Medicine international conference (2025)

Asia Economy

Cho Jun-young (조준영)

Co-CEO, HMR Asia

As of Dec 2023

—

Asia Economy

Governance Overview

ItemStatus

Committee structure

Not publicly disclosed (KOSDAQ companies below KRW 2tn in assets are not required to have an audit committee)

Major Shareholders

HolderSharesStakeDateSource

Acro New Technology Fund No.241

4,782,49612.75%

28 Sep 2026

DART filing via Special Times

— pro forma after the KRW 10bn placement (23 Dec 2026)

16,519,585 (pre-consolidation basis)

About 33.5%

Scheduled

Money Today via Nate

Acro Fund No.241's largest investor

아인스팩 (AinsFac)

50.95% of the fund

2026

Dealsite (28 Aug 2026)

Lamicus and related parties (prior controller)

Sold 4,552,496 (Lamicus) and 230,000 (Jeong Jip-hun)

12.14% and 0.61% before the sale

Before 28 Sep 2026

DART via Special Times

Chris F&C (크리스에프앤씨) and 1 other

—

8.71% (as reported in Korean Wikipedia's 2025-basis infobox)

—

Korean Wikipedia

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorCountryPositioning vs. XoMotion

Wandercraft (Atalante)

France

Most direct technological peer: self-balancing, hands-free exoskeleton for rehabilitation

Ekso Bionics

US

Established rehab exoskeleton supplier; crutch-assisted designs

Lifeward (formerly ReWalk Robotics)

Israel/US

Personal and rehab exoskeletons; US reimbursement pathway

Cyberdyne (HAL)

Japan

Bio-signal-driven exoskeleton; strong presence in Japan and APAC

Angel Robotics

Korea (KOSDAQ-listed)

Domestic wearable-robot leader; direct Korean competitor for hospital channels

Hyundai Motor Group robotics (X-ble line)

Korea

Large-group wearable-robot programme

Fourier Intelligence

China

Rehabilitation robotics platform with APAC reach

Peer Comparison FY2025

MetricAinsFac CNSWandercraft

Latest revenue

KRW 4.77bn (FY2025)

Not publicly disclosed (private)

Revenue growth

−81.1% (FY2025)

—

Operating margin

−112.3% (FY2025)

—

“—” = not publicly disclosed.

Recent Developments

Status caveat.

Company Snapshot

$3.4M

Revenue

22

Employees

2001

Founded

SWOT Analysis

Strengths

  • Book equity well above market value: Equity KRW 65.6bn (30 Jun 2026) vs. market cap about KRW 23bn; P/B about 0.35–0.37x (Bloter; Valueline)
  • New controlling shareholder committing fresh capital: KRW 33.96bn paid for 12.75%, plus a committed KRW 10bn placement due 23 Dec 2026 (DART via Special Times)
  • Differentiated robotics technology: XoMotion self-balancing hands-free exoskeleton; CES 2025 Innovation Award (Asia Economy)
  • Regulatory approval in a developed market: Health Canada approval for XoMotion-R, with a first sales contract (Asia Economy, Jan 2025)
  • Optional upside from an affiliate IPO: HMR's KOSDAQ technology-special IPO mandate with Eugene Investment & Securities (Oct 2025)
  • Bio IP being built: Beno Bio macular-degeneration injection patent (Jun 2026); Pan-KRAS programme selected for a 2026 collaboration programme

Weaknesses

  • Very small and shrinking revenue base: TTM revenue KRW 3.64bn (Jun 2026), down from KRW 11.22bn a year earlier (Valueline)
  • Chronic operating losses: Operating losses every year FY2022–FY2025; H1 2026 loss widened 74% to KRW 2.82bn (Butler.works; Dealsite)
  • Large non-operating losses: FY2025 net loss KRW 24.03bn vs. operating loss KRW 5.36bn (Wikipedia; Butler.works)
  • Robotics not commercialised in Korea: HMR Asia had zero revenue and about KRW 0.5bn net loss in H1 2026 (Bloter)
  • Eroding equity: Equity fell from KRW 71.9bn to KRW 65.6bn in six months (Bloter)
  • Limited disclosure and no coverage: No analyst coverage (StockHub: 0 reports); key line items not visible in public summaries

Opportunities

  • Capital injection enabling new businesses: KRW 10bn placement; articles amended to add semiconductor, battery, ESS and recycling objects (Bloter)
  • Monetising the HMR stake: IPO preparation (Oct 2025)
  • Growth in rehab robots across ASEAN and APAC: Robotimize partnership covering Singapore, Malaysia and Indonesia (Asia Economy)
  • FDA and MFDS approvals: XoMotion-R approvals in progress (Asia Economy, Oct 2025)
  • Licensing of bio assets: Beno Bio patent and programme selection (2026)
  • Restoring listing compliance: 2:1 consolidation and 5:1 reduction lift the theoretical price about 10x (₩678 → about ₩6,780; Money Today)

Threats

  • Delisting under the 2026 rules: "At risk" designation 12 Aug 2026; KOSDAQ market-cap floor rises to KRW 30bn in Jan 2027 vs. about KRW 23bn now (Digital Daily)
  • Massive potential dilution: Authorised shares raised to 5bn; CB/BW limits raised to KRW 5tn each (Bloter)
  • Deal-execution risk: Balance payment delayed twice (Aug 27 → Sep 14 → Sep 28) (Money Today via Nate)
  • Trading-integrity concerns: Top-10 accounts made up 65.32% of trading on 19 Aug 2026; investment-caution designation (Dealsite)
  • Minority-shareholder value transfer: About 600% control premium vs. 10% discounted placement (Chosun Biz)
  • Consolidations often fail to hold prices: 83.3% of completed Korean share consolidations since Feb 2026 saw prices fall after relisting (Financial News, citing Hanwha Investment & Securities)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 Apr 2025Announces HMR Asia–Robotimize partnership (signed 27 Mar)First ASEAN distribution channel for XoMotion
29 May 2025Share price ₩1.82k; market cap KRW 70.7bn; down 44.6% over one year (Simply Wall St)Reference point before the later collapse
Jul 2025KRW 30bn CB and rights-issue plan with Haemil IB (CB payment 13 Aug; rights payment 28 Oct; issue price ₩1,876)Would have changed control. Press questioned the investor's capacity.
Sep 2025HMR exhibits at Humanoid 2025 (COEX, Seoul)Visibility for the robotics business
Sep 2025HMR founder Edward Park gives the keynote at the Korean Academy of Rehabilitation Medicine international conferenceClinical-community engagement
2025HMR Asia selected for the K-Humanoid AllianceEcosystem positioning
30 Oct 2025HMR appoints Eugene Investment & Securities for a KOSDAQ technology-special IPOPotential value-realisation event for the stake
Mar 2026 (FY report)FY2025: revenue KRW 4.77bn (−81%), operating loss KRW 5.36bn, net loss KRW 24.03bnSevere deterioration; large non-operating losses
2026Acquires the Geumyoung E&C duct business for about KRW 0.8bnAdds a revenue line (46% of Q2 2026 revenue)
2026Beno Bio selected for the 2026 Global Company Collaboration Program (Pan-KRAS)Bio pipeline signal; no financial impact disclosed
Jun 2026Beno Bio registers a macular-degeneration injection composition patentIP milestone
3 Jul 2026SPA: 12.75% sold to Acro Fund No.241 at ₩7,100 per share (KRW 33.96bn)Change of control at about a 600% premium
3 Jul 2026Board approves a KRW 10bn placement to Acro at ₩852 (11,737,089 shares; one-year lock-up)Dilution of about 31% (pre-consolidation basis); new working capital
6 Jul 2026Stock hits its daily limit (+29.96% intraday to ₩1,323) and closes +10% at ₩1,138Market reaction to the control change
7 Jul 2026Chosun Biz reports controversy over the controller's premium versus discounted new sharesGovernance and minority-shareholder concern
8 Jul 2026Close falls to ₩996, below ₩1,000Starts the count toward penny-stock administrative designation
10 Jul 2026Substantial-shareholding report filedOwnership disclosure
23 Jul 2026Close ₩760Near the 52-week low
30 Jul 2026Single sales/supply contract disclosedConstruction backlog (value not publicly disclosed in reviewed sources)
12 Aug 2026KRX notice: "at risk of administrative-issue designation" (price below ₩1,000 for 25 trading days)Delisting-pathway risk under rules in force since 1 Jul 2026
14 Aug 2026H1 2026 report: revenue −44% YoY; operating loss −74% wider. EGM notice amended.Continued deterioration
19 Aug 2026Volume up 8.8x; top-10 accounts make up 65.32% of trading. Investment-caution designation follows.Market-integrity concern (Dealsite)
About 20 Aug 2026Closes at ₩1,003 for one session, narrowly avoiding administrative designationTemporary relief
Late Aug 2026Balance-payment date moved from 27 Aug to 14 Sep 2026Deal-execution uncertainty
28 Aug 2026Close ₩943, back below ₩1,000Penny-stock risk returns
14 Sep 2026Payment date moved again to 28 Sep. Stated capital-reduction purpose changed (correction filing).Further uncertainty
15 Sep 2026EGM agenda published: rename, new directors, new business objects, authorised shares to 5bn, CB/BW/EB limits to KRW 5tn, 5:1 capital reduction, 2:1 consolidationFull recapitalisation and repositioning
22 Sep 2026Price ₩678; market cap about KRW 24.6bn (Valueline)Near the KOSDAQ KRW 20bn market-cap floor
28 Sep 2026Control transfer closes; Acro Fund No.241 becomes largest shareholderChange of control completed
29 Sep 2026EGM; company renamed AinsFac CNS Co., Ltd. Stock +23.41% to ₩949.New corporate identity
12 Oct 2026Close ₩619 (−7.61%); 52-week range ₩550–₩2,550Shares near their lows before the consolidation
16 Oct 2026 (scheduled)2:1 share consolidationMechanically lifts the price above ₩1,000
29 Oct 2026 (scheduled)5:1 capital reductionShares fall to about 3.75m; theoretical price ×10 in total
23 Dec 2026 (scheduled)KRW 10bn placement payment by AcroAcro stake rises to about 33.5%

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

3 charts
Income Statement (FY2021–FY2025): Revenue fell from KRW 26,700 Mn in FY2021 to KRW 4,770 Mn in FY2025.
Benoholdings, Inc. — Income Statement (FY2021–FY2025)
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue26,70021,8009,90025,3004,770
Operating income1,500-1,900-7,000-9,700-5,360
Net income8,600-21,900-7,900-3,600-24,030

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Investing.com — BenoHoldings (206400) quote pages · kr.investing.com
  2. Valueline — 206400 income statement / valuation (valueline.co.kr)
  3. StockHub — 206400 · stockhub.kr
  4. Simply Wall St — BENO TNR (simplywall.st)
  5. Butler.works — 베노티앤알 company page (butler.works)
  6. Bullstory — 206400 · bullstory.io
  7. Korean Wikipedia — 아인스팩CNS (ko.wikipedia.org)
  8. Dealsite (20 Aug 2026) (dealsite.co.kr)
  9. Dealsite (28 Aug 2026) (dealsite.co.kr)
  10. Bloter (15 Sep 2026) (bloter.net)
  11. Money Today via Nate (15 Sep 2026) (m.news.nate.com)
  12. Digital Today — largest shareholder change (28 Sep 2026) (digitaltoday.co.kr)
  13. Digital Today — trade name change (29 Sep 2026) (digitaltoday.co.kr)
  14. Special Times — DART largest-shareholder-change text (specialtimes.co.kr)
  15. ChickStock — DART filing summary (chickstockfi.com)
  16. Edaily (EN) — limit-up (6 Jul 2026) (en.edaily.co.kr)
  17. Edaily (KR) — SPA (3 Jul 2026) (edaily.co.kr)
  18. Edaily (KR) — limit-up and placement (edaily.co.kr)
  19. Chosun Biz via Daum (7 Jul 2026) (v.daum.net)
  20. Sidae Ilbo (Jun 2023) (sidae.com)
  21. Asia Economy (25 Nov 2020) (core.asiae.co.kr)
  22. Asia Economy — HMR Asia hiring (Dec 2023) (core.asiae.co.kr)
  23. Asia Economy — Alticast investment (Dec 2024) (core.asiae.co.kr)
  24. Asia Economy — Alticast progress (Jan 2025) (core.asiae.co.kr)
  25. Asia Economy — Robotimize (Apr 2025) (core.asiae.co.kr)
  26. Asia Economy — HMR IPO mandate (Oct 2025) (core.asiae.co.kr)
  27. Asia Economy — Alticast 2026 (view.asiae.co.kr)
  28. eToday — XoMotion launch (Oct 2023) (etoday.co.kr)
  29. eToday — humanoid robots (Apr 2024) (etoday.co.kr)
  30. News Tomato — XoMotion (Oct 2023) (newstomato.com)
  31. IB Tomato — Haemil IB financing (Jul 2025) (newstomato.com)
  32. iNews24 — Entermate SPAC filing (Oct 2015) (inews24.com)
  33. iNews24 — Entermate IPO briefing (Dec 2015) (inews24.com)
  34. Digital Daily — administrative designations (Aug 2026) (ddaily.co.kr)
  35. SBS Biz (16 Aug 2026) (biz.sbs.co.kr)
  36. Financial News (16 Aug 2026) (fnnews.com)
  37. TokenPost (Aug 2026) (tokenpost.kr)
  38. MyDailyByte — 206400 (mydailybyte.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.